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Context: The mitochondrial uncoupling protein-3 (UCP3) has been
implicated in the protection of the mitochondrial matrix against lipid-
induced mitochondrial damage. Recent evidence points toward mi-
tochondrial aberrations as a major contributor to the development of
insulin resistance and diabetes, and UCP3 is reduced in diabetes.
Objective: We compared skeletal muscle UCP3 protein levels in
prediabetic subjects [i.e. impaired glucose tolerance (IGT)], diabetic
patients, and healthy controls and examined whether rosiglitazone
treatment was able to restore UCP3.
Patients, Design, Intervention: Ten middle-aged obese men with
type 2 diabetes mellitus [age, 61.4  3.1 yr; body mass index (BMI),
29.8  2.9 kg/m2], nine IGT subjects (age, 59.0  6.6 yr; BMI, 29.7 
3.0 kg/m2), and 10 age- and BMI-matched healthy controls (age,
57.3  7.4 yr; BMI, 30.1  3.9 kg/m2) participated in this study. After
baseline comparisons, diabetic patients received rosiglitazone (2  4
mg/d) for 8 wk.
Main Outcome Measures: Muscle biopsies were sampled to deter-
mine UCP3 and mitochondrial protein (complex I–V) content.
Results: UCP3 protein content was significantly lower in prediabetic
IGT subjects and in diabetic patients compared with healthy controls
(39.0  28.5, 47.2  24.7, and 72.0  23.7 arbitrary units, respectively;
P  0.05), whereas the levels of the mitochondrial protein complex I–V
were similar between groups. Rosiglitazone treatment for 8 wk sig-
nificantly increased insulin sensitivity and muscle UCP3 content
(from 53.2  29.9 to 66.3  30.9 arbitrary units; P  0.05).
Conclusion: We show that UCP3 protein content is reduced in pre-
diabetic subjects and type 2 diabetic patients. Eight weeks of rosigli-
tazone treatment restores skeletal muscle UCP3 protein in diabetic
patients. (J Clin Endocrinol Metab 91: 1520–1525, 2006)
IN THE EARLY years after the discovery of human un-coupling protein-3 (UCP3) in 1997, the physiological
function of UCP3 was thought to be in the regulation of
energy metabolism and body weight. However, 8 yr later,
data gathered in human experiments and (transgenic) ani-
mals have revealed that the function of skeletal muscle UCP3
is most likely related to fatty acid metabolism and/or reac-
tive oxygen species (ROS) production. Based on the available
literature on the regulation of UCP3, we have recently hy-
pothesized that skeletal muscle UCP3 protects mitochondria
against lipid-induced mitochondrial damage (1). Thus, UCP3
is consistently up-regulated in conditions in which, because
of exceeding the oxidative capacity, fatty acids accumulate in
the sarcoplasm (2). On the other hand, UCP3 is down-reg-
ulated when fat oxidative capacity is improved (2). In con-
ditions where fatty acids accumulate in the sarcoplasm, the
load of fatty acids on the mitochondrial membranes increases
and, because membranes are lipid bilayers, fatty acids can
enter the mitochondrial matrix via the “flip-flop” mechanism
(3). The mitochondrial matrix is also the site where ROS are
formed, and fatty acids present in the matrix or in the mi-
tochondrial inner membranes would be highly susceptible to
become peroxidized by ROS. Because the resulting lipid per-
oxides are highly reactive (4) and can cause damage to mi-
tochondrial RNA, DNA, and mitochondrial structures, it is
important to keep the import of fatty acids into the matrix
and/or the level of ROS production within limits, especially
under conditions of high fatty acid availability. To date, there
is no consensus regarding the exact physiological function of
UCP3. Nevertheless, several independent groups hypothe-
sized that skeletal muscle UCP3 could play a crucial role in
preventing such lipid-induced mitochondrial damage albeit
via different mechanisms. Thus, we (2) and Himms-Hagen
and Harper (5) have postulated the hypothesis that UCP3
exports nonmetabolizable fatty acids from the mitochondrial
matrix to prevent them from being peroxidized, albeit that
the source of the mitochondrial fatty acids is different in these
two hypothesis. In addition, Goglia and Skulachev (6) have
suggested that UCP3 exports lipid peroxides from the mi-
tochondrial matrix before they can damage the oxidative
machinery in the matrix. Alternatively, Brand and colleagues
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(7) have suggested that UCP3 directly lowers ROS produc-
tion after being activated by lipid peroxides. Regardless of
the exact function of UCP3, all three hypotheses predict that
a lack of skeletal muscle UCP3 would result in lipid-induced
oxidative damage to the mitochondria. Indeed, UCP3 ablated
mice are characterized by increased levels of muscular lipid
peroxidation and oxidative damage to proteins and DNA (8).
Because type 2 diabetic patients are characterized by in-
creased levels of plasma fatty acids and a low fat oxidative
capacity (9), high levels of skeletal muscle UCP3 would be
anticipated to prevent lipid-induced mitochondrial damage.
Consistent with this idea, two studies have shown increased
levels of muscular UCP3 mRNA in diabetic subjects (10, 11),
but another study found a reduced skeletal muscle UCP3
mRNA expression (12). To further address this issue, we
measured UCP3 protein levels in type 2 diabetic subjects and
healthy controls and found that UCP3 protein was decreased
by approximately 50% in muscle of diabetic patients (13).
Given the putative function of UCP3 in the protection against
lipid-induced mitochondrial damage, it is interesting to note
that insulin-resistant subjects are characterized by increased
mitochondrial damage (14) and an increased degree of lipid
peroxidation in muscle (15), suggesting that low UCP3 in
muscle may be part of the etiology of type 2 diabetes. A
prerequisite for a role of UCP3 in mitochondrial damage and
dysfunction would be that UCP3 levels are already reduced
in the prediabetic state, thereby stressing the role of UCP3
during the progression of the prediabetic state toward overt
diabetes. Hence, in this study, we examined UCP3 protein
levels in prediabetic subjects, i.e. subjects with impaired glu-
cose tolerance (IGT).
At present, thiazolidinediones (TZD) are frequently pre-
scribed to treat type 2 diabetic patients. TZDs lower glucose
mainly due to an improved insulin-stimulated glucose dis-
posal into skeletal muscle, either indirectly or directly via
peroxisome proliferator-activated receptor  (PPAR), the
main target for TZDs. A recent paper showed that, in healthy
rats, acute ip injections of high dosages of TZD increased
mRNA expression of skeletal muscle UCP3 (16). Therefore,
the aims of the present study were to confirm the reduced
levels of UCP3 mRNA and protein in skeletal muscle of
diabetic patients and to examine whether UCP3 is already
reduced in the prediabetic state. In addition, we examined
whether prolonged treatment with TZD, at therapeutical




Ten middle-aged obese men with type 2 diabetes mellitus and 10 age-
and body mass index (BMI)-matched healthy controls participated in
this study. For baseline comparison of UCP3 protein levels, both groups
were compared with nine glucose intolerant subjects (IGT), which have
been described previously (17) (see Table 1 for characteristics). Diabetic
subjects were diagnosed with diabetes at least 1 yr before the study, and
had well-controlled diabetes. Two subjects were treated with metformin
only, four with a sulfonylurea only, and four with metformin and sul-
fonylurea. IGT was diagnosed with an oral glucose tolerance test ac-
cording to World Health Organization criteria. Control subjects had
normal glucose homeostasis, ax determined by a standard oral glucose
tolerance test, and had no family history of diabetes. Before the start of
the study, a medical history and physical examination were performed,
a resting electrocardiogram was taken, and a fasting blood sample was
drawn. Subjects with uncontrolled hypertension, active cardiovascular
disease, liver dysfunction (alanine aminotransferase or aspartate ami-
notransferase 2.5 times upper limit), increased creatinine levels, or on
medication known to interfere with the goals of the study (e.g. cortico-
steroids) were excluded from participation. None of the participants
performed regular intensive exercise or followed a strict diet or weight
reduction program for at least 3 months before the start of the study. The
Medical Ethical Review Committee of Maastricht University approved
the study protocol, and all subjects gave their written informed consent
before the start of the study.
Study design
In glucose intolerant subjects (IGT), only skeletal muscle UCP3 pro-
tein content was determined and compared with the diabetic patients
and healthy controls. For other measurements, the healthy subjects
served as baseline controls to the diabetic patients and were not treated
with rosiglitazone. In the diabetic patients, any prior anti-diabetes med-
ication was discontinued 14 d before the baseline experimental trial.
After baseline measurements, diabetic subjects received rosiglitazone
(2  4 mg/d) for 8 wk, after which all measurements were repeated.
Unfortunately, two patients did not complete the trial due to mild
gastrointestinal complaints (n  1) and uncontrolled hyperglycemia
(n  1). Therefore, all data on the effect of rosiglitazone is on n  8 only.
Muscle biopsies
After an overnight fast, a percutaneous needle muscle biopsy of the
vastus lateralis muscle was taken, according to the technique by Berg-
ström et al. (18). The tissue specimen was frozen immediately in iso-
pentane kept at its melting point in liquid nitrogen and stored at80 C.
For diabetic patients and controls, muscle biopsy was taken before the
clamp.
Hyperinsulinemic-euglycemic clamp
At 0800 h, after an overnight fast, subjects report to the laboratory by
car or by bus. After taking a muscle biopsy, cannulas were inserted, one
into each antecubital vein for the infusion of tracer, insulin, and glucose,
and a third one was inserted retrogradely into a superficial dorsal hand
vein for arterialized blood sampling. After a first blood sample, a primed
constant infusion of 6,6-2H2-glucose was initiated (0.04 mg/kgmin) for
300 min; blood was sampled at t  90, 100, 110, and 120 min and substrate
oxidation was measured by indirect calorimetry (Omnical, Maastricht,
The Netherlands). At t  120 min, a primed constant infusion of insulin
(Actrapid; Bagsvaerd, Novo Nordisk, Denmark) was started (40 mU/
m2min), and glucose levels were clamped by variable coinfusion of 20%
glucose with tracer added (controls: 5.6  0.3 mmol/liter; diabetic sub-
jects: 6.5  1.3 and 6.7  1.9 mmol/liter before and after, respectively).
At t  270, 280, 290, and 300 min, blood was again sampled and indirect
calorimetry was performed.
Metabolic flexibility
Both in the basal state and during insulin stimulation, substrate
oxidation was measured by indirect calorimetry, and carbohydrate and
fat oxidation was calculated. In healthy subjects, fat oxidation is the
predominant source contributing to energy expenditure in the fasted
TABLE 1. Baseline subjects characteristics
Control IGT Diabetic
Age (yr) 57.3  7.4 59.0  6.6 61.4  3.1
BMI (kg/m2) 30.1  3.9 29.7  3.0 29.8  2.9
VO2max (ml/kgmin) 33.7  5.3 28.1  3.2
a 26.8  2.0a
Glucose (mmol/liter) 5.8  0.4 6.2  1.3 10.1  2.3a
HbA1c (%) NA NA 7.0  1.0
Duration diabetes (yr) – – 5.9  4.1
Data are expressed as mean  SD. NA, Not available.
a P  0.05 compared to control.
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state, whereas insulin will switch substrate use to carbohydrate oxida-
tion. This flexibility to switch from predominantly fat oxidation to glu-
cose oxidation is termed “metabolic flexibility”. Here we measured the
stimulating effect of insulin on glucose oxidation and the suppressing
effect of insulin on fat oxidation in control subjects and in type 2 diabetic
patients as a measure of metabolic flexibility, and these measurements
were repeated in type 2 diabetic patients treated with rosiglitazone for
8 wk.
Calculations
To calculate plasma glucose rate of appearance and rate of disap-
pearance, Steele’s single pool non-steady-state equations, adapted for
use with stable isotopes, were used, as no isotopic steady-state was
present. Volume of distribution was assumed to be 0.160 literkg1 for
glucose. The glucose metabolic clearance rate (MCR) equals the rate of
disappearance divided by the steady-state plasma glucose concentra-
tion. Endogenous glucose production (EGP) was calculated as rate of
appearance minus the exogenous glucose infusion rate. Total carbohy-
drate and lipid oxidation were calculated according to the table of
nonprotein respiratory quotient.
Muscle analysis
Total RNA was extracted from skeletal muscle biopsies using TRIzol
reagent (Invitrogen, Breda, The Netherlands). One microgram of RNA
was reverse transcribed to cDNA using Random Hexomer primers and
a Stratascript enzyme (Stratagene, Amsterdam, The Netherlands).
Quantitative PCR was performed using an MX3000p thermal cycler
system and Brilliant SYBER Green QPCR Master Mix (Stratagene). The
PCR conditions consisted of one denaturing cycle at 90 C for 10 min
followed by 40 cycles, consisting of denaturing at 90 C for 30 sec,
annealing at the predetermined temperature for 60 sec, and elongation
at 72 C for 60 sec. At the end of the PCR, the samples were subjected to
a melting curve analysis. To control for any variations due to efficiencies
of the RT and PCR, acidic ribosomal phosphoprotein PO (36B4) was used
as internal control. The CT was calculated by subtracting the CT for
36B4 from the CT for the gene of interest. The relative expression of UCP3
is calculated using the expression 2CT and reported in arbitrary units
(AU). PCR runs were performed in triplicate.
For UCP3 protein determination, muscle biopsies were homogenized
in ice-cold Tris-EDTA buffer at pH 7.4, and then the homogenates were
sonicated for 15 sec. Subsequently, two volumes of each skeletal muscle
homogenate and one volume of SDS-sample buffer were boiled for 4
min. Next, 13% polyacrylamide gels containing 0.1% SDS were loaded
with equal amounts of protein from each sample, and electrophoresis
was performed using a Mini-Protean 3 Electrophoresis Cell (Bio-Rad
Laboratories, Hercules, CA). After gel electrophoresis, the gel was
scanned, and the optical density of the 43-kDa band, previously im-
muno-identified to represent actin, was assessed. Then, a second gel was
prepared and loaded with the sample volume (which had been recal-
culated based on the optical density of the actin band), after which
Western blotting was performed using a Mini Trans-Blot Electrophoretic
Transfer Cell (Bio-Rad Laboratories) as described previously (19). We
used a rabbit polyclonal UCP3 antibody (code 1331; kindly provided by
L. J. Slieker, Eli Lilly, Indianapolis, IN) prepared against a 20-amino acid
peptide (human sequence amino acid 147–166). For a detailed descrip-
tion of the selectivity and specificity checks see previous reports (19, 20).
Cytochrome c level, as a marker of mitochondrial content, was measured
comparably using a rabbit polyclonal cytochrome c antibody (BD
PharMingen, Woerden, NL). The ND6 subunit of complex I, the 30-kDa
Ip subunit of complex II, the 47-kDa core protein 2 of complex III, subunit
II of cytochrome c oxidase (COXII), and the  subunit of the F1F0 ATP
synthase (complex V) were measured using monoclonal antibodies (Mi-
toSciences, Eugene, OR). All proteins were expressed as AU.
Blood samples
Blood was collected in tubes containing EDTA. Plasma was imme-
diately centrifuged at high speed, frozen in liquid nitrogen and stored
at 80 C for later analyses. Insulin concentrations were measured using
RIA (Linco Research, St. Charles, MO). Free fatty acids (FFA) were
determined using the Wako Nefa C test kit (Wako Chemicals, Neuss,
Germany), and plasma glucose was determined using the hexokinase
method (LaRoche, Basel, Switzerland).
Statistics
Data are presented as mean  sd. Selected parameters were com-
pared in healthy controls and diabetic patients using Student’s t tests.
Results before and after treatment were analyzed using a paired Stu-
dent’s t test. Association between variables was evaluated with regres-
sion analysis. Statistical significance was set at P  0.05.
Results
Blood parameters
During the 2-wk wash-out period before the start of the
first experimental clamp, fasting plasma glucose and glyco-
sylated hemoglobin (HbA1c) levels increased in the diabetic
subjects (glucose 7.6  1.3 to 10.1  2.3 mmol/liter, P  0.01;
HbA1c 7.0  0.8 to 7.2  0.8%, P  0.05). By definition, type
2 diabetic subjects had significantly higher fasting plasma
glucose (10.1  2.3 vs. 5.8  0.4 mmol/liter, P  0.01) and
insulin levels (17.9  6.6 vs. 12.3  2.7 mU/liter, P  0.05)
compared with healthy controls. No difference was observed
in fasting plasma FFA level (563  157 vs. 511  144 mol/
liter, P  0.33). After 8 wk of treatment with rosiglitazone,
fasting insulin tended to decrease in type 2 diabetic subjects
(from 17.9  6.6 to 13.8  6.6 mU/liter, P  0.07), but plasma
glucose (10.0  3.0 to 8.5  1.6 mmol/liter, P  0.17) and
HbA1c (7.4  1.0 to 7.8  1.2%, P  0.17) were not signifi-
cantly affected. No changes were observed in body weight
(from 91.8  7.6 to 92.5  8.3 kg, P  0.52). Plasma FFA levels
were significantly decreased after 8 wk of rosiglitazone treat-
ment (from 569  165 to 456  145 mol/liter, P  0.05).
Insulin sensitivity and metabolic flexibility
As expected, insulin sensitivity (MCR) was significantly
lower in type 2 diabetic subjects compared with healthy
controls (3.30  1.66 vs. 5.22  1.95 ml/kgmin in diabetic
patients and controls, respectively, P  0.05). Eight weeks of
rosiglitazone treatment increased the MCR from 3.36  1.88
to 4.19  1.79 ml/kgmin (Fig. 1; P  0.06), indicating res-
toration of insulin sensitivity. EGP was increased in the di-
abetic patients in the basal state (13.1  4.1 vs. 8.4  1.4
mol/kgmin for diabetes and control, respectively; P 
0.01), but not during the clamp (3.4  1.4 vs. 3.6  2.6
mol/kgmin, respectively; P  0.85). Rosiglitazone treat-
ment resulted in a reduced basal EGP (13.2  4.5 to 8.7  1.8
mol/kgmin; P  0.05), whereas clamping EGP was not
significantly altered (3.3  1.5 to 1.5  2.3 mol/kgmin; P 
0.16). Metabolic flexibility, i.e. the capacity to switch from
predominantly fat oxidation in the fasting state to glucose
oxidation in the insulin-stimulated state was also reduced in
type 2 diabetic patients compared with healthy controls.
Thus, the stimulating effect of insulin on glucose oxidation
was significantly lower in type 2 diabetic patients vs. controls
(3.3  2.4 vs. 6.0  3.0 mol/kgmin in diabetic patients
and controls, respectively; P  0.05), whereas insulin sup-
pression of lipid oxidation was also significantly lower in
diabetic subjects (0.22  0.16 vs. 0.47  0.26 mol/kgmin
in diabetic patients and controls, respectively; P  0.05).
Rosiglitazone treatment improved metabolic flexibility;
the stimulating effect of insulin on glucose oxidation was
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significantly greater after rosiglitazone treatment (from
3.4  2.6 to 5.3  2.3 mol/kgmin; P  0.05), whereas
insulin suppression of lipid oxidation was also significantly
improved by rosiglitazone (0.23  0.18 to 0.36  0.15
mol/min; P  0.05). The improved metabolic flexibility is
also indicated by the more pronounced increase in respira-
tory quotient after rosiglitazone treatment, during transition
from the basal to the insulin-stimulated state (from 0.84 
0.05 to 0.88  0.06 before treatment, vs. from 0.84  0.02 to
0.91  0.03 after 8 wk rosiglitazone; P  0.05).
UCP3 and mitochondrial protein levels
UCP3 mRNA expression was reduced by 42% in type 2
diabetic patients compared with healthy, age- and BMI-
matched controls (1.59  1.1 vs. 2.75  0.93 AU in diabetic
patients and controls, respectively; P  0.05). This corre-
sponds well with the approximately 35% reduction in UCP3
protein content in type 2 diabetic patients compared with
healthy, age- and BMI-matched controls (47.2  24.7 vs.
72.0  23.7 AU in diabetic patients and controls, respectively;
P  0.05; Fig. 2). Importantly, no significant differences in
protein levels of any of the other mitochondrial proteins
examined (complex I–V and cytochrome c) were observed
between type 2 diabetic patients and healthy controls (Table
2). In addition, we also report that UCP3 protein content is
already significantly reduced by approximately 46% in pre-
diabetic subjects (IGT) compared with age- and BMI-
matched healthy controls (39.0  28.5 vs. 72.0  23.7 AU; P 
0.05; Fig. 2), whereas cytochrome c levels were not signifi-
cantly different between prediabetic subjects (IGT) and
healthy controls (33.6  9.5 vs. 41.0  25.1 AU; P  0.49).
Eight weeks of rosiglitazone treatment tended to increase
the mRNA expression of UCP3 by 37% (from 1.52  1.04 to
2.09  1.25 AU; P  0.10), whereas this effect was statistically
significant at the UCP3 protein level (from 53.2  29.9 to
66.3  30.9 AU; P  0.05; Fig. 1). Again, no effect of rosigli-
tazone treatment on protein levels of the other mitochondrial
proteins (complex I to V and cytochrome c) was observed
(Table 3). There were no correlations between plasma FFA
levels, insulin sensitivity, metabolic flexibility, and UCP3
protein levels at any time point.
Discussion
Based on the putative functions of UCP3 and its associa-
tion with fatty acid metabolism, increased levels of skeletal
muscle UCP3 protein are anticipated in diabetic subjects who
are characterized by high plasma fatty acid levels and low fat
oxidative capacity (9). However, here we confirmed our pre-
vious finding (13) that type 2 diabetic patients have reduced
levels of skeletal muscle UCP3 mRNA and protein when
compared with age- and BMI-matched healthy controls. Im-
portantly, the difference in UCP3 protein was not simply due
to a reduced mitochondrial content, as indicated by the sim-
ilar levels of mitochondrial proteins of complex I–V in our
(relatively “healthy”) diabetic patients and nondiabetic con-
trols. The reduction of UCP3 in skeletal muscle of diabetic
TABLE 2. UCP3 and mitochondrial protein complex I–V in
control (n  10) and diabetic (n  10) subjects at baseline
Control Diabetic P
UCP3 72.0  23.7 47.2  24.7 0.035
Cytochrome c 39.6  17.7 41.0  25.1 0.96
Complex I 2.7  1.9 1.8  0.8 0.18
Complex II 4.7  2.3 4.6  1.9 0.95
Complex III 44.3  16.6 39.7  0.56 0.56
Complex IV 15.3  8.5 12.9  5.8 0.46
Complex V 48.7  17.5 43.8  16 0.52
Data are expressed as mean  SD.
FIG. 1. Insulin sensitivity (A; MCR in
milliliters per kilogram per minute)
and skeletal muscle UCP3 protein con-
tent (B; AU) before and after 8 wk of
rosiglitazone treatment in diabetic sub-
jects (n  8). Both MCR (P  0.06) and
UCP3 (P  0.05) were increased after
treatment.
FIG. 2. Skeletal muscle UCP3 protein content (AU) in healthy con-
trols (n  10), prediabetic IGT subjects (n  9), and type 2 diabetic
patients (n  10). UCP3 was lower in IGT and DM compared to
controls (P  0.05).







/article/91/4/1520/2843547 by guest on 03 O
ctober 2021
patients was accompanied by decreased insulin sensitivity
and reduced metabolic flexibility, i.e. a reduced capacity to
switch from predominantly fat oxidation in the fasting state
to glucose oxidation in the insulin-stimulated state. Impor-
tantly, we also show that a reduction to a similar extent of
UCP3 protein content can be observed in glucose-intolerant
subjects, which are generally regarded as prediabetic sub-
jects. In addition, we show that rosiglitazone treatment re-
sults in an up-regulation of UCP3 protein content by, on
average 25%, accompanied by increased insulin sensitivity
and improved metabolic flexibility. To the best of our knowl-
edge, this is the first time that reduced UCP3 protein content
in prediabetic subjects and/or an up-regulation of UCP3
protein content in type 2 diabetic patients by a therapeutic
treatment has been shown and it suggests that a reduced
level of UCP3 in type 2 diabetes is indeed part of the etiology
of the disease.
The reduction of skeletal muscle UCP3 protein content in
type 2 diabetic patients is remarkable and cannot simply be
explained by the physiological regulation of UCP3 protein.
Thus, skeletal muscle UCP3 protein levels are inversely re-
lated to fat oxidative capacity (21), are low in type 1 muscle
fibers (22), and are reduced by endurance training (23, 24).
On the other hand, UCP3 is up-regulated by increased levels
of plasma fatty acids (25) and high-fat diets (19), and is high
in type 2 muscle fibers (22) and in patients with decreased fat
oxidative capacity (26). Based on all these and other obser-
vations, an increased level of UCP3 protein content would be
expected in type 2 diabetic patients. Therefore, the reduction
of UCP3 in type 2 diabetic patients may reflect a pathological
condition, which is further stressed by the finding that ros-
iglitazone treatment, which improved metabolic character-
istics in these patients, restored UCP3 protein levels. How-
ever, it cannot be excluded that other factors, such as
hyperinsulinemia or hyperglycemia, are responsible for the
reduced levels of UCP3 in diabetes. To this end, we deter-
mined UCP3 protein content in subjects who are prone to
develop diabetes. Full-blown type 2 diabetes is preceded by
a long-term state of IGT; up to 60% of people who develop
diabetes have IGT 5 yr before the diagnosis of type 2 diabetes
(27). We found that UCP3, but not cytochrome c protein
content, was reduced to the same extent in IGT and type 2
diabetic subjects when compared with age- and BMI-
matched controls. This indicates that low UCP3 levels are
already present in a population at risk for developing dia-
betes suggesting that UCP3 is indeed involved in the etiology
of type 2 diabetes mellitus.
As mentioned above, one of the most potent stimulators of
UCP3 expression is the level of plasma FFA. Acute fasting
and intralipid infusion both rapidly up-regulated UCP3 (28).
Also in the recent study of Brunmair et al. (16), showing that
acute injection of rosiglitazone in muscle of rats induced
UCP3 mRNA expression, plasma fatty acids were elevated,
which might partly have explained the effect of rosiglitazone
on UCP3. In the present human study, however, plasma fatty
acids levels were significantly reduced by rosiglitazone, most
likely due to a TZD-induced improved uptake and storage
in white adipose tissue. Therefore, plasma fatty acids could
not have been responsible for the up-regulation of UCP3 in
the current study. Alternatively, the reduction of plasma
glucose and insulin levels after TZD treatment may have
been responsible for the up-regulation of UCP3, as hyper-
glycemia has been shown to down-regulate UCP3 in human
neuroblastoma cells (29), but data on glucose/insulin regu-
lation of human skeletal muscle UCP3 is lacking. More likely,
rosiglitazone may exert a direct effect on skeletal muscle,
despite the fairly low expression of PPAR in skeletal mus-
cle. The importance of PPAR in skeletal muscle is under-
scored by the finding that muscle-specific PPAR knockout
mice develop muscular insulin resistance and do not enhance
insulin-stimulated glucose uptake upon TZD treatment (30).
In addition, it is of importance to note that the promoter of
the UCP3 gene contains a PPAR response element, enabling
direct effects of the PPAR agonist rosiglitazone (31, 32).
In regard to the physiological function of skeletal muscle
UCP3, we have recently hypothesized (1) that the reduced
level of UCP3 observed in diabetes contributes to the in-
creased mitochondrial damage (14) and decreased mitochon-
drial function (15) observed in this disease. In support of this
is the finding that mice lacking UCP3 are indeed character-
ized by increased levels of mitochondrial oxidative damage
and lipid peroxidation (8). Although we did not examine
these parameters directly in the present study, metabolic
flexibility—an indicator of oxidative capacity—was signifi-
cantly reduced in type 2 diabetic subjects compared with age-
and BMI-matched healthy controls. In addition, the restora-
tion of UCP3 protein levels after 8 wk of rosiglitazone treat-
ment was accompanied by an enhanced insulin stimulation
of glucose oxidation and insulin suppression of fat oxidation,
indicating improved metabolic flexibility, which requires
proper mitochondrial function. The finding that the reduced
UCP3 protein content in skeletal muscle of diabetic patients
was accompanied by a reduced insulin sensitivity and de-
creased metabolic flexibility, and that the TZD-induced resto-
ration of UCP3 was accompanied by improved insulin resis-
tance and increased metabolic flexibility, is indeed compatible
with a role of UCP3 in the protection of lipid-induced mito-
chondrial damage, but clearly future studies are needed to
examine whether an up-regulation of UCP3 by TZDs indeed is
accompanied by an improved mitochondrial function.
In conclusion, we confirm that skeletal muscle UCP3 pro-
tein is reduced in type 2 diabetic patients compared with age-
and BMI-matched healthy controls. Moreover, we show for
the first time that the reduction in UCP3 protein content can
already be found in the prediabetic state. In addition, we
showed that rosiglitazone treatment up-regulates UCP3 pro-
tein content in skeletal muscle of type 2 diabetic patients.
Further studies are required to establish whether a reduction
TABLE 3. UCP3 and mitochondrial protein complex I–V before
and after TZD treatment in diabetic patients (n  8)
Before After P
UCP3 53.2  29.9 66.3  30.9 0.043
Cytochrome c 45.7  22.3 44.4  16.3 0.85
Complex I 2.0  0.8 1.3  1.1 0.15
Complex II 4.6  1.91 3.5  2.6 0.38
Complex III 41.4  20.5 37.1  27.7 0.52
Complex IV 14.0  5.9 11.2  7.2 0.31
Complex V 42.5  17.6 45.0  21.4 0.69
Data are expressed as mean  SD.
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of UCP3 plays a significant role in the mitochondrial dys-
function that is observed in type 2 diabetes mellitus.
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